<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>GLP-1: what changed | Grey Peptides</title>
    <link>https://greypeptides.com/changes/#e-glp-1</link>
    <atom:link href="https://greypeptides.com/changes/glp-1.xml" rel="self" type="application/rss+xml" />
    <description>News, regulatory alerts, corrections and new guides about GLP-1 on Grey Peptides, newest first.</description>
    <language>en-us</language>
    <lastBuildDate>Fri, 09 Oct 2026 12:00:00 +0000</lastBuildDate>
    <ttl>1440</ttl>
    <item>
      <title>Regulatory alert: US FDA: FDA published a major revision of Import Alert 66-80, which lets it detain GLP-1 bulk ingredients from foreign sites not on its Green List without examination, updating the Green List criteria and adding product codes, including one for orforglipron.</title>
      <link>https://greypeptides.com/regulatory/alerts/#fda-import-alert-66-80-revised</link>
      <guid isPermaLink="false">greypeptides-changes-glp-1-alert-fda-import-alert-66-80-revised</guid>
      <pubDate>Fri, 09 Oct 2026 12:00:00 +0000</pubDate>
      <category>Regulatory alert</category>
      <description>The alert governs the raw ingredient that compounders import, not a finished product a patient buys. FDA says 21% of the 48 GLP-1 ingredient sites it reviewed were noncompliant, and that some sites registered, offered ingredients for import, refused records requests and deregistered.</description>
    </item>
    <item>
      <title>Regulatory alert: US FDA: FDA warned a Houston compounding pharmacy that its tirzepatide with niacinamide and semaglutide with vitamin B12 appear to be essentially copies of approved GLP-1 drugs, made in volumes suggesting the added vitamin is pretextual. Posted September 22.</title>
      <link>https://greypeptides.com/regulatory/alerts/#fda-wl-vitamin-glp1-copies</link>
      <guid isPermaLink="false">greypeptides-changes-glp-1-alert-fda-wl-vitamin-glp1-copies</guid>
      <pubDate>Fri, 18 Sep 2026 12:00:00 +0000</pubDate>
      <category>Regulatory alert</category>
      <description>Adding a vitamin does not by itself make a compounded GLP-1 lawful. The statute's condition is a prescriber's documented, patient-specific significant difference; pre-written prescriber determinations were part of FDA's case.</description>
    </item>
    <item>
      <title>Regulatory alert: China (State Council): China's revised drug regulations (Order No. 828) took effect, barring online retail and online prescribing of higher-risk medicines.</title>
      <link>https://greypeptides.com/regulatory/alerts/#china-online-sales-rules</link>
      <guid isPermaLink="false">greypeptides-changes-glp-1-alert-china-online-sales-rules</guid>
      <pubDate>Fri, 15 May 2026 12:00:00 +0000</pubDate>
      <category>Regulatory alert</category>
      <description>The online route through which GLP-1 injections had been reaching weight-loss buyers in China was closed.</description>
    </item>
    <item>
      <title>Regulatory alert: US FDA: FDA warned a state-licensed compounding pharmacy that released products, including a compounded tirzepatide injection, among nine lots that failed sterility testing.</title>
      <link>https://greypeptides.com/regulatory/alerts/#fda-wl-503a-sterility</link>
      <guid isPermaLink="false">greypeptides-changes-glp-1-alert-fda-wl-503a-sterility</guid>
      <pubDate>Fri, 16 Jan 2026 12:00:00 +0000</pubDate>
      <category>Regulatory alert</category>
      <description>A compounded GLP-1 is only as safe as the pharmacy's sterile practice; checking that a pharmacy is licensed and has no recent FDA letter is part of choosing one.</description>
    </item>
    <item>
      <title>Regulatory alert: US FDA: FDA launched a 'Green List' import alert (66-80): GLP-1 ingredients such as semaglutide and tirzepatide from foreign sites it has not found compliant can be detained without physical examination.</title>
      <link>https://greypeptides.com/regulatory/alerts/#fda-glp1-green-list</link>
      <guid isPermaLink="false">greypeptides-changes-glp-1-alert-fda-glp1-green-list</guid>
      <pubDate>Fri, 05 Sep 2025 12:00:00 +0000</pubDate>
      <category>Regulatory alert</category>
      <description>It is aimed at ingredients for compounding, not at personal parcels: ingredients from sites on the Green List can still be imported.</description>
    </item>
    <item>
      <title>Regulatory alert: European Union (EMA and HMA): The European Medicines Agency and the Heads of Medicines Agencies warned of a sharp rise in illegal medicines advertised and sold online as GLP-1 receptor agonists.</title>
      <link>https://greypeptides.com/regulatory/alerts/#ema-illegal-glp1-warning</link>
      <guid isPermaLink="false">greypeptides-changes-glp-1-alert-ema-illegal-glp1-warning</guid>
      <pubDate>Wed, 03 Sep 2025 12:00:00 +0000</pubDate>
      <category>Regulatory alert</category>
      <description>In the EU, GLP-1 drugs are prescription medicines, to be bought only from authorised pharmacies or retailers on a prescription.</description>
    </item>
    <item>
      <title>Regulatory alert: US FDA: FDA's enforcement discretion for outsourcing facilities compounding semaglutide ended.</title>
      <link>https://greypeptides.com/regulatory/alerts/#503b-semaglutide-discretion-ends</link>
      <guid isPermaLink="false">greypeptides-changes-glp-1-alert-503b-semaglutide-discretion-ends</guid>
      <pubDate>Thu, 22 May 2025 12:00:00 +0000</pubDate>
      <category>Regulatory alert</category>
      <description>This is when mass-market compounded semaglutide ended in the US, not in 2026.</description>
    </item>
    <item>
      <title>Regulatory alert: US FDA: FDA's enforcement discretion for 503A pharmacies compounding semaglutide copies ended when a court denied a preliminary injunction.</title>
      <link>https://greypeptides.com/regulatory/alerts/#503a-semaglutide-discretion-ends</link>
      <guid isPermaLink="false">greypeptides-changes-glp-1-alert-503a-semaglutide-discretion-ends</guid>
      <pubDate>Thu, 24 Apr 2025 12:00:00 +0000</pubDate>
      <category>Regulatory alert</category>
      <description>State-licensed pharmacies may no longer routinely compound copies of semaglutide; a compounded product needs a patient-specific clinical difference documented by the prescriber.</description>
    </item>
    <item>
      <title>Regulatory alert: US FDA: FDA's enforcement discretion for outsourcing facilities compounding tirzepatide ended.</title>
      <link>https://greypeptides.com/regulatory/alerts/#503b-tirzepatide-discretion-ends</link>
      <guid isPermaLink="false">greypeptides-changes-glp-1-alert-503b-tirzepatide-discretion-ends</guid>
      <pubDate>Wed, 19 Mar 2025 12:00:00 +0000</pubDate>
      <category>Regulatory alert</category>
      <description>Outsourcing facilities lost the shortage-era route to compounding tirzepatide.</description>
    </item>
    <item>
      <title>Regulatory alert: US FDA: FDA's enforcement discretion for 503A pharmacies compounding tirzepatide copies ended when a court denied a preliminary injunction.</title>
      <link>https://greypeptides.com/regulatory/alerts/#503a-tirzepatide-discretion-ends</link>
      <guid isPermaLink="false">greypeptides-changes-glp-1-alert-503a-tirzepatide-discretion-ends</guid>
      <pubDate>Wed, 05 Mar 2025 12:00:00 +0000</pubDate>
      <category>Regulatory alert</category>
      <description>State-licensed pharmacies lost the routine route to compounding tirzepatide first.</description>
    </item>
    <item>
      <title>Regulatory alert: US FDA: FDA declared the semaglutide shortage resolved.</title>
      <link>https://greypeptides.com/regulatory/alerts/#semaglutide-shortage-resolved</link>
      <guid isPermaLink="false">greypeptides-changes-glp-1-alert-semaglutide-shortage-resolved</guid>
      <pubDate>Fri, 21 Feb 2025 12:00:00 +0000</pubDate>
      <category>Regulatory alert</category>
      <description>The shortage listing was the legal hook for compounding copies; its end started the clock on the enforcement dates that followed.</description>
    </item>
  </channel>
</rss>
